


Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound of formula I:



FORMULA I

or a pharmaceutically acceptable salt, enantiomer, diastereomer or in vivo hydrolysable ester or mixture thereof, ~~wherein,~~ wherein:

~~R¹ represents~~ is selected from the group consisting of C₆₋₁₀ aryl, C₅₋₁₀ heteroaryl or C₅₋₁₀ heterocyclic groups, said aryl, heteroaryl and ~~heterocyclic~~ heterocyclic groups optionally substituted with 1 to 3 groups of R^a.

~~R^a represents~~ is selected from the group consisting of C₁₋₆ alkyl, halogen, ~~OH~~ hydroxy, aryl(C₁₋₆)alkyl, (C₁₋₆)alkoxy, (C₁₋₆)alkoxy(C₁₋₆)alkyl, halo(C₁₋₆)alkyl, nitro, amino, mono- or di-N-(C₁₋₆)alkylamino, acylamino, acyloxy, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C₁₋₆)alkylcarbamoyl, (C₁₋₆)alkoxycarbonyl, aryloxy carbonyl, ureido, guanidine, sulphonylamino, aminosulphonyl, (C₁₋₆)alkylthio, (C₁₋₆)alkylsulphanyl, (C₁₋₆)alkylsulphonyl, heterocyclyl, and heterocyclyl(C₁₋₆)alkyl groups; and

~~R represents~~ is selected from the group consisting of C₁₋₈ alkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₅₋₁₀ heteroaryl, ~~or and~~ C₅₋₁₁ heterocyclic groups, said heteroaryl and ~~heterocyclic~~ heterocyclic groups are optionally substituted with 1 to 3 groups of R^a and said ~~alkyl, optionally~~ C₁₋₈ alkyl groups are substituted with ~~1-3~~ 1 to 3 groups selected from the group consisting of aryl, heterocyclyl, (C₁₋₆)alkylthio, cyano, heteroaryl, guanidino, ((1-aminoethyl)carbonyl)amino, ((aminomethyl)carbonyl)amino,

RECEIVED
CENTRAL FAX CENTER

MAY 09 2007

Serial No. 10/509,972

Case No. 21111YP

((2-amino)prop-2-yl) carbonyl)amino, acetamido, 4-(aminomethyl)phenyl, thio, t-butyl sulfonyl, (C₂₋₆)alkenylthio, (C₂₋₆)alkynylthio, amino, mono- or di-(C₁₋₆)alkylamino, arylthio, heterocyclylthio, (C₁₋₆)alkoxy, aryl(C₁₋₆)alkoxy, aryl(C₁₋₆)alkylthio, cycloalkyl, cycloalkenyl, carboxy and esters thereof, hydroxy and halogen groups.

2. (Currently Amended) ~~A-The compound according to claim 1~~
~~wherein claim 1, wherein R is a heterocycloalkyl and all other variables are as originally~~
~~described.~~

3. (Currently Amended) ~~A-The compound according to claim 1~~
~~wherein claim 1, wherein R is a heteroaryl and all other variables are as originally~~
~~described.~~


4. (Currently Amended) ~~A-The compound according to claim 1~~
~~wherein claim 1, wherein R¹ is a phenyl group optionally substituted with 1-3-1 to 3~~
~~groups of R^a and R is a heterocycloalkyl, or heteroaryl heterocycloalkyl or heteroaryl~~
~~group.~~

5. (Currently Amended) ~~A-The compound according to claim 1~~
~~wherein claim 1, R¹ is a phenyl group substituted with 1 to 3 groups of methoxy, halogen,~~
~~methyl, ethyl, propyl, butyl, naphthyl, 5-(2-pyridyl)thiophen-2-yl or a mixture thereof, and~~
~~R is a heterocycloalkyl or heteroaryl group.~~























6. (Currently Amended) ~~A-The compound according to claim 1~~
~~which claim 1, wherein the compound is selected from the group consisting of:~~
~~N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;~~
~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;~~
~~N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-~~
~~acetamide;~~
~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-~~
~~acetamide;~~
~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-(S)-~~

cyclopropylbutyramide; and from
compounds provided in tables 1 and 2 below

Table 1























Example #	R ₁	R ₂
3		
4		
5		
6		
7		
8		
9		

10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		





















Serial No. 10/509,972





















Case No. 21111YP

21		
22		
23		
24		
25		
26		
27		
28		
29		
30		

Serial No. 10/509,972























Case No. 21111YP

31		
32		
33		
34		
35		
36		
37		
38		
39		
40		

41		
42		
43		
44		
45		
46		
47		
48		
49		
50		





















Serial No. 10/509,972





















Case No. 21111YP

51		
52		
53		
54		
55		
56		
57		
58		
59		
60		
61		

Serial No. 10/509,972























Case No. 21111YP

62		
63		
64		
65		
66		
67		
68		
69		
70		
71		

72		
73		
74		
75		
76		
77		
78		
79		
80		
81		





















Serial No. 10/509,972

Case No. 21111YP

82		
83		
84		
85		
86		
87		
88		
89		
90		
91		
92		





















Serial No. 10/509,972

Case No. 21111YP

93		
94		
95		
96		
97		
98		
99		
100		
101		
102		

























Serial No. 10/509,972

Case No. 21111YP



























103		
104		
105		
106		
107		
108		
109		
110		
111		
112		

Serial No. 10/509,972

Case No. 21111YP

113		
114		
115		
116		
117		
118		
119		
120		
121		
122		
123		
124		

Serial No. 10/509,972
Case No. 21111YP

125		
126		
127		
128		
129		
130		
131		
132		
133		
134		
135		
136		
137		

Serial No. 10/509,972

Case No. 21111YP
























138		
139		
140		
141		
142		
143		
144		

Table 2



Example #	R ₁ R ₁	R ₂ R ₂
146		Me

147		Me
148		Me
149		H
150		Me
151		Me
152		Me
153		Me

and pharmaceutically acceptable salts, enantiomers, ~~diastereomers or in~~ diastereomers, in vivo hydrolysable esters or and mixtures thereof.

7. (Currently Amended) ~~A-The compound according to claim 6~~
~~which claim 6, wherein the compound is selected from the group consisting of:~~
~~N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;~~
~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;~~
~~N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-~~
~~acetamide;~~
~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-~~
~~acetamide;~~
~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-(S)-~~
~~cyclopropylbutyramide; and pharmaceutically acceptable salts, enantiomers,~~
~~diastereomers or in~~ diastereomers, in vivo hydrolysable esters or and mixtures thereof.


8. (Currently Amended) ~~A-The compound according to claim 7 which~~
~~is claim 7, wherein the compound is selected from the group consisting of:~~
~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide; or~~

N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide; and pharmaceutically acceptable salts, enantiomers, ~~diastereomers or in~~ diastereomers, in vivo hydrolysable esters or and mixtures thereof.

9. (Currently Amended) A composition ~~according to claim 1,~~ comprising a compound of ~~formula I~~ according to claim 1 and a pharmaceutically acceptable carrier.

10. (Currently Amended) A method of inhibiting the activity of lethal factor (LF) released from bacterial in a ~~mammal comprising administration~~ mammal, the method comprising:

administering to a patient in need thereof a therapeutically effective amount of a compound of structural formula I



FORMULA I

or a pharmaceutically acceptable salt, enantiomer, diastereomer or in vivo hydrolysable ester or mixture thereof, wherein,

R^1 ~~represents~~ is selected from the group consisting of C_{6-10} aryl, C_{5-10} heteroaryl ~~or and~~ C_{5-10} heterocyclic groups, said aryl, heteroaryl and heterocyclic groups ~~heterocyclicly~~ optionally substituted with 1 to 3 groups of R^a ,

R^a ~~represents~~ is selected from the group consisting of C_{1-6} alkyl, halogen, OH, aryl(C_{1-6})alkyl, (C_{1-6})alkoxy, (C_{1-6})alkoxy(C_{1-6})alkyl, halo(C_{1-6})alkyl, nitro, amino, mono- or di-N-(C_{1-6})alkylamino, acylamino, acyloxy, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C_{1-6})alkylcarbamoyl, (C_{1-6})alkoxycarbonyl, aryloxy carbonyl, ureido, guanidine, sulphonylamino, aminosulphonyl, (C_{1-6})alkylthio, (C_{1-6})alkylsulphonyl, (C_{1-6})alkylsulphonyl, heterocyclyl, and heterocyclyl(C_{1-6})alkyl groups; and


Serial No. 10/509,972

Case No. 21111YP





















~~R represents~~ is selected from the group consisting of C₁₋₈ alkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₃₋₁₀ heteroaryl, or C₅₋₁₁ heterocyclyl, said heteroaryl and heterocyclyl groups are optionally substituted with 1 to 3 groups of R^a and R^b, and said alkyl, optionally C₁₋₈ alkyl groups are substituted with 1 to 3 groups selected from the group consisting of aryl, heterocyclyl, (C₁₋₆)alkylthio, cyano, heteroaryl, guanidino, ((1-aminoethyl)carbonyl)amino, ((aminomethyl)carbonyl)amino, ((2-amino)prop-2-yl)carbonyl)amino, acetamido, 4-(aminomethyl)phenyl, thio, t-butyl sulfonyl, (C₂₋₆)alkenylthio, (C₂₋₆)alkynylthio, amino, mono- or di-(C₁₋₆)alkylamino, arylthio, heterocyclylthio, (C₁₋₆)alkoxy, aryl(C₁₋₆)alkoxy, aryl(C₁₋₆)alkylthio, cycloalkyl, cycloalkenyl, carboxy and esters thereof, hydroxy and halogen groups.























11. (Currently Amended) ~~A The method according to elaim 11~~
~~wherein claim 10, wherein~~ the compound is selected from the group consisting of:
~~N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;~~
~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;~~
~~N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-~~
~~acetamide;~~
~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-~~
~~acetamide;~~
~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-(S)-~~
~~cyclopropylbutyramide; and from~~
compounds provided in tables 1 and 2 below

Table 1

























Example #	R1R1	R2R2
3		

4		
5		
6		
7		
8		
9		
10		
11		
12		
13		

14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		





















Serial No. 10/509,972

Case No. 21111YP

25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		























Serial No. 10/509,972

Case No. 21111YP





















36		
37		
38		
39		
40		
41		
42		
43		
44		
45		

Serial No. 10/509,972

Case No. 21111YP.





















46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		

Serial No. 10/509,972
Case No. 21111YP























57		
58		
59		
60		
61		
62		
63		
64		
65		
66		























Serial No. 10/509,972





















Case No. 21111YP

67		
68		
69		
70		
71		
72		
73		
74		
75		
76		

Serial No. 10/509,972
Case No. 21111YP























77		
78		
79		
80		
81		
82		
83		
84		
85		
86		
87		

88		
89		
90		
91		
92		
93		
94		
95		
96		
97		
98		

























99		
100		
101		
102		
103		
104		
105		
106		
107		
108		

Serial No. 10/509,972

Case No. 21111YP

























109		
110		
111		
112		
113		
114		
115		
116		
117		
118		
119		

Serial No. 10/509,972
Case No. 21111YP

120		
121		
122		
123		
124		
125		
126		
127		
128		
129		
130		
131		

Serial No. 10/509,972

Case No. 21111YP

132		
133		
134		
135		
136		
137		
138		
139		
140		
141		
142		
143		

Serial No. 10/509,972

Case No. 21111YP













Table 2



Example #	R1R1	R2R2
146		Me
147		Me
148		Me
149	 NH ₂	H
150		Me
151		Me
152		Me
153		Me

and pharmaceutically acceptable salts, enantiomers, ~~diastereomers or in~~ diastereomers, in vivo hydrolysable esters or and mixtures thereof.

Serial No. 10/509,972

Case No. 21111YP

12. (Currently Amended) ~~A~~ The method according to claim 11 ~~wherein claim 11, wherein~~ the compound is selected from the group consisting of:
N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;
N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;
N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide;
N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide;
N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-(S)-cyclopropylbutyramide; and pharmaceutically acceptable salts, enantiomers, ~~diastereomers or in diastereomers,~~ in vivo hydrolysable esters ~~or and~~ mixtures thereof.
13. (Currently Amended) ~~A~~ The method according to claim 12 wherein claim 12, wherein the compound is selected from the group consisting of:
N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide; or
N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide; and pharmaceutically acceptable salts, enantiomers, ~~diastereomers or in diastereomers,~~ in vivo hydrolysable esters ~~or and~~ mixtures thereof.
14. (Currently Amended) ~~A~~ The method according to claim 10 wherein claim 10, wherein said administering further comprises administering the compound of formula I is combined in combination with one or more known drugs selected from beta-lactams, aminoglycosides, inhibitors of beta-lactamase, renal tubular blocking agents and inhibitors or metabolizing enzymes, N-acylated amino acids.
15. (Currently Amended) ~~A~~ The method according to claim 14 wherein claim 14, wherein the known drugs are selected from the group consisting of imipenem, meropenem, vancomycin, cilastatin, cefoxitin, penicillin, clavulanic acid, probenecid, tetracycline, ciprofloxacin, and norfloxacin or a mixture thereof, wherein when imipenem is used as a drug it is used in combination with cilastatin as PRIMAXIN®.